Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
arcticnovartis

  • Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-negative disease
  • New 48-week efficacy and safety data from the Phase III APPLY-PNH trial of investigational oral monotherapy iptacopan in anti-C5-treated adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia
  • Nearly 4 year follow-up efficacy and safety results from end of study treat
/by
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
arcticnovartis

  • In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo1
  • Treatment with remibrutinib led to significant improvement in symptom control, as early as Week 2 and sustained up to Week 121
  • Remibrutinib was well-tolerated and demonstrated a favorable safety profile with rates of overall adverse events comparable to placebo and balanced liver
/by
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
arcticnovartis

  • In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo1
  • Treatment with remibrutinib led to significant improvement in symptom control, as early as Week 2 and sustained up to Week 121
  • Remibrutinib was well-tolerated and demonstrated a favorable safety profile with rates of overall adverse events comparable to placebo and balanced liver
/by
Mentoring matters: how we grow together at Novartis

Mentoring matters: how we grow together at Novartis
kabagke1

/by
Mentoring matters: how we grow together at Novartis

Mentoring matters: how we grow together at Novartis
kabagke1

/by
Belonging here: How Novartis helped me come out as a transgender woman

Belonging here: How Novartis helped me come out as a transgender woman
kabagke1

/by
Belonging here: How Novartis helped me come out as a transgender woman

Belonging here: How Novartis helped me come out as a transgender woman
kabagke1

/by
How I found my true purpose at Novartis

How I found my true purpose at Novartis
kabagke1

/by
How I found my true purpose at Novartis

How I found my true purpose at Novartis
kabagke1

/by
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
arcticnovartis

  • FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21
  • As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares2
  • HS is a chronic, progressive and often painful disease that may affect 1 in 100 people worldwide3
/by